Rights and permissions Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material
Semaglutide 2.4 mg (Wegovy) has demonstrated cardiovascular benefits in the SELECT trial, though this benefit should not be assumed for all medications in this class
Table 1E summarizes the implantable technologies involved in the development of a formulation for sustained delivery
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
Figure 4 presents a flow chart outlining the currently available GLP-1 receptor agonists
The market is expanding at a CAGR of 28.54% between 2025 and 2034